Myelofibrosis: Difference between revisions
m Bot: Automated text replacement (-Category:Primary care +) |
|||
| (3 intermediate revisions by one other user not shown) | |||
| Line 8: | Line 8: | ||
}} | }} | ||
{{Myelofibrosis}} | {{Myelofibrosis}} | ||
{{CMG}}{{AE}}{{Sab}}{{MJK}} | {{CMG}} {{AE}} {{Sab}}; {{MJK}}; {{SR}} | ||
{{SK}} Agnogenic myeloid metaplasia; AMM; Myeloid metaplasia; Myeloid metaplasia, NOS; Myelofibrosis with myeloid metaplasia; MMM; Assmann's disease; Chronic granulocytic-megakaryocytic myelosis; Chronic granulocytic megakaryocytic myelosis; Megakaryocytic myelosclerosis; Chronic idiopathic myelofibrosis; CIMF; Heuck-Assmann disease; Idiopathic myelofibrosis; Primary myelofibrosis; PMF; Prefibrotic primary myelofibrosis; Secondary myelofibrosis; Myelosclerosis; Osteomyelofibrosis; Osteomyelosclerosis; Myeloproliferative disorder | {{SK}} Agnogenic myeloid metaplasia; AMM; Myeloid metaplasia; Myeloid metaplasia, NOS; Myelofibrosis with myeloid metaplasia; MMM; Assmann's disease; Chronic granulocytic-megakaryocytic myelosis; Chronic granulocytic megakaryocytic myelosis; Megakaryocytic myelosclerosis; Chronic idiopathic myelofibrosis; CIMF; Heuck-Assmann disease; Idiopathic myelofibrosis; Primary myelofibrosis; PMF; Prefibrotic primary myelofibrosis; Secondary myelofibrosis; Myelosclerosis; Osteomyelofibrosis; Osteomyelosclerosis; Myeloproliferative disorder | ||
==[[Myelofibrosis overview|Overview]]== | ==[[Myelofibrosis overview|Overview]]== | ||
| Line 36: | Line 36: | ||
==Treatment== | ==Treatment== | ||
[[Myelofibrosis medical therapy|Medical Therapy]] | [[Myelofibrosis surgery|Surgery]] | [[Myelofibrosis prevention|Prevention]] | [[Myelofibrosis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Myelofibrosis future or investigational therapies|Future or Investigational Therapies]] | [[Myelofibrosis medical therapy|Medical Therapy]] | [[Myelofibrosis surgery|Surgery]] | [[Myelofibrosis primary prevention|Primary Prevention]] | [[Myelofibrosis secondary prevention|Secondary Prevention]] | [[Myelofibrosis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Myelofibrosis future or investigational therapies|Future or Investigational Therapies]] | ||
==Case Studies== | ==Case Studies== | ||
| Line 51: | Line 51: | ||
[[Category:Neurosurgery]] | [[Category:Neurosurgery]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
Latest revision as of 06:34, 28 July 2020
For patient information, click here
Template:DiseaseDisorder infobox
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]; Mohamad Alkateb, MBBCh [3]; Sujit Routray, M.D. [4]
Synonyms and keywords: Agnogenic myeloid metaplasia; AMM; Myeloid metaplasia; Myeloid metaplasia, NOS; Myelofibrosis with myeloid metaplasia; MMM; Assmann's disease; Chronic granulocytic-megakaryocytic myelosis; Chronic granulocytic megakaryocytic myelosis; Megakaryocytic myelosclerosis; Chronic idiopathic myelofibrosis; CIMF; Heuck-Assmann disease; Idiopathic myelofibrosis; Primary myelofibrosis; PMF; Prefibrotic primary myelofibrosis; Secondary myelofibrosis; Myelosclerosis; Osteomyelofibrosis; Osteomyelosclerosis; Myeloproliferative disorder
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Myelofibrosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies